CNTA
Price:
$17.53
Market Cap:
$2.31B
Centessa Pharmaceuticals plc, a clinical-stage pharmaceutical company, discovers, develops, and delivers medicines to patients. Its registrational pipeline products include Lixivaptan, a vasopressin V2 receptor small molecule inhibitor that is in Phase III clinical development for the treatment of autosomal dominant polycystic kidney disease; and SerpinPC, an activated protein C inhibitor, which is in Phase IIa clinical development for the treatment of hemophilia A and B. The company also has emerging pipeline products under clinical proof of concept stage comprising LB101, a PD-L1xCD47 LockBody, as well as LB201, a PD-L1xCD3 LockBody, which are designed to selectively drive potent CD47 and ...[Read more]
Industry
Biotechnology
IPO Date
2021-05-28
Stock Exchange
NASDAQ
Ticker
CNTA
According to Centessa Pharmaceuticals plc’s latest financial reports and current stock price. The company's current PE Ratio is -11.53. This represents a change of 59.38% compared to the average of -7.23 of the last 4 quarters.
The mean historical PE Ratio of Centessa Pharmaceuticals plc over the last ten years is -116.14. The current -11.53 PE Ratio has changed 892.76% with respect to the historical average. Over the past ten years (40 quarters), CNTA's PE Ratio was at its highest in in the March 2020 quarter at 0. The PE Ratio was at its lowest in in the September 2020 quarter at -361.29.
Average
-116.14
Median
-5.07
Minimum
-291.80
Maximum
-1.34
Discovering the peaks and valleys of Centessa Pharmaceuticals plc PE Ratio, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.
Maximum Annual Increase = 278.38%
Maximum Annual PE Ratio = -1.34
Minimum Annual Increase = -99.05%
Minimum Annual PE Ratio = -291.80
Year | PE Ratio | Change |
---|---|---|
2023 | -5.07 | 278.38% |
2022 | -1.34 | -49.53% |
2021 | -2.65 | -99.05% |
2020 | -279.84 | -4.10% |
The current PE Ratio of Centessa Pharmaceuticals plc (CNTA) is less than than its 3-year, greater than its 5-year, and greater than its 10-year historical averages
3-year avg
-3.02
5-year avg
-116.14
10-year avg
-116.14
Centessa Pharmaceuticals plc’s PE Ratio is less than Century Therapeutics, Inc. (-0.67), greater than Edgewise Therapeutics, Inc. (-22.63), less than C4 Therapeutics, Inc. (-2.68), less than Mineralys Therapeutics, Inc. (-3.92), less than Cullinan Oncology, Inc. (-4.82), greater than NewAmsterdam Pharma Company N.V. (-13.31), less than Sutro Biopharma, Inc. (-1.24), less than Opthea Limited (-1.15), less than HilleVax, Inc. (-0.61), greater than Nuvalent, Inc. (-24.55), greater than Tarsus Pharmaceuticals, Inc. (-15.55), less than Genfit S.A. (122.03), greater than Gracell Biotechnologies Inc. (-29.25), less than Theseus Pharmaceuticals, Inc. (-6.29), less than Monte Rosa Therapeutics, Inc. (-4.90), less than Design Therapeutics, Inc. (-7.36), less than Erasca, Inc. (-4.40), greater than Crinetics Pharmaceuticals, Inc. (-15.55), less than Entrada Therapeutics, Inc. (12.91), greater than Disc Medicine, Inc. (-18.46), less than Larimar Therapeutics, Inc. (-3.90),
Company | PE Ratio | Market cap |
---|---|---|
-0.67 | $86.73M | |
-22.63 | $2.84B | |
-2.68 | $286.59M | |
-3.92 | $600.21M | |
-4.82 | $691.16M | |
-13.31 | $2.59B | |
-1.24 | $154.20M | |
-1.15 | $4.57B | |
-0.61 | $92.64M | |
-24.55 | $5.96B | |
-15.55 | $2.08B | |
122.03 | $190.49M | |
-29.25 | $989.87M | |
-6.29 | $181.50M | |
-4.90 | $438.66M | |
-7.36 | $351.62M | |
-4.40 | $701.16M | |
-15.55 | $5.00B | |
12.91 | $653.35M | |
-18.46 | $1.90B | |
-3.90 | $252.67M |
One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Centessa Pharmaceuticals plc using the financials and key metrics that matter to you in a single view.
The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:
Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.
Get your free trial here.
The easiest way to analyze a company like Centessa Pharmaceuticals plc or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.
Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.
Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.
What is the PE Ratio?
How can you use the PE Ratio?
What is Centessa Pharmaceuticals plc's PE Ratio?
How is the PE Ratio calculated for Centessa Pharmaceuticals plc (CNTA)?
What is the highest PE Ratio for Centessa Pharmaceuticals plc (CNTA)?
What is the 3-year average PE Ratio for Centessa Pharmaceuticals plc (CNTA)?
What is the 5-year average PE Ratio for Centessa Pharmaceuticals plc (CNTA)?
How does the current PE Ratio for Centessa Pharmaceuticals plc (CNTA) compare to its historical average?